U.S. markets open in 2 hours 20 minutes
  • S&P Futures

    4,135.25
    -6.50 (-0.16%)
     
  • Dow Futures

    32,797.00
    +5.00 (+0.02%)
     
  • Nasdaq Futures

    13,120.50
    -62.75 (-0.48%)
     
  • Russell 2000 Futures

    1,939.00
    -2.10 (-0.11%)
     
  • Crude Oil

    91.63
    +0.87 (+0.96%)
     
  • Gold

    1,807.10
    +1.90 (+0.11%)
     
  • Silver

    20.59
    -0.02 (-0.09%)
     
  • EUR/USD

    1.0228
    +0.0033 (+0.33%)
     
  • 10-Yr Bond

    2.7650
    0.0000 (0.00%)
     
  • Vix

    21.87
    +0.72 (+3.40%)
     
  • GBP/USD

    1.2106
    +0.0025 (+0.21%)
     
  • USD/JPY

    134.9000
    -0.0730 (-0.05%)
     
  • BTC-USD

    23,395.69
    -647.17 (-2.69%)
     
  • CMC Crypto 200

    543.83
    +0.95 (+0.18%)
     
  • FTSE 100

    7,481.41
    -0.96 (-0.01%)
     
  • Nikkei 225

    27,999.96
    -249.28 (-0.88%)
     

AVEO Oncology to Announce Second Quarter 2022 Financial Results on August 4, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
AVEO Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc.

BOSTON, July 28, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report second quarter 2022 financial results on Thursday, August 4, 2022. AVEO’s management team will host a conference call and audio webcast at 4:30 p.m. ET on Thursday, August 4, 2022, to discuss the financial results and provide a business update.

The call can be accessed by dialing (877) 423-9813 (U.S. and Canada) or (201) 689-8573 (international). The passcode for the conference call is 13730553. To access the live webcast, or the subsequent archived recording, please visit the Calendar of Events sub-section within the Investors section of the AVEO website at www.aveooncology.com.

About AVEO Pharmaceuticals, Inc.

AVEO is a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of AVEO within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Actual results or events could differ materially due to a number of important factors, including risks discussed in the sections titled “Risk Factor Summary,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources” included in AVEO’s most recent Annual Report on Form 10-K, its quarterly reports on Form 10-Q and in other filings that AVEO makes with the SEC. The forward-looking statements in this press release represent AVEO’s views as of the date of this press release. AVEO anticipates that subsequent events and developments may cause its views to change. While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing AVEO’s views as of any date other than the date of this press release.

AVEO Investor Relations Contact: 
Hans Vitzthum
LifeSci Advisors, LLC
Hans@LifeSciAdvisors.com    
(617) 430-7578

Source: AVEO Oncology